The Coretec Group Inc. (CRTG) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 12, 2020
Document Information [Line Items]
Entity Registrant Name	CORETEC GROUP INC.
Entity Central Index Key	0001375195
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		204,950,642
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 23,655	$ 58,149
Prepaid expenses	178,400	88,821
Total current assets	202,055	146,970
Property and equipment, net		126
Other assets:
Patents, net	1,079,083	1,139,255
Goodwill	166,000	166,000
Deposits-other	1,260	3,575
Total other assets	1,246,343	1,308,830
Total Assets	1,448,398	1,455,926
Current liabilities:
Notes payable	69,545	39,138
Accounts payable and accrued expenses	491,654	615,815
Total current liabilities	561,199	654,953
Long term debt:
Notes payable - related party, net of discounts	240,973	120,508
Total Liabilities	802,172	775,461
Stockholders' equity:
Preferred stock, Series A convertible, $0.0002 par value, 500,000 shares authorized; 345,000 shares issued and outstanding at September 30, 2020 and December 31, 2019	69	69
Common stock $0.0002 par value, 1,500,000,000 shares authorized; 204,450,642 and 193,521,506 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	40,890	38,704
Additional paid-in capital	7,353,503	6,135,885
Accumulated deficit	(6,748,236)	(5,494,193)
Total Stockholders' Equity	646,226	680,465
Total Liabilities and Stockholders' Equity	$ 1,448,398	$ 1,455,926

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.0002	$ 0.0002
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares issued (in shares)	345,000	345,000
Preferred stock, shares outstanding (in shares)	345,000	345,000
Common stock, par value (in dollars per share)	$ 0.0002	$ 0.0002
Common stock, shares authorized (in shares)	1,500,000,000	1,500,000,000
Common stock, shares issued (in shares)	204,450,642	193,521,506
Common stock, shares outstanding (in shares)	204,450,642	193,521,506

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income:
Revenue
Expenses:
Research and development	37,197	25,623	117,187	77,740
General and administrative	316,376	868,556	780,491	1,211,810
Interest	80,531	41,209	357,615	230,011
Total expenses	434,104	935,388	1,255,293	1,519,561
Other income			1,250
Net loss	$ (434,104)	$ (935,388)	$ (1,254,043)	$ (1,519,561)
Loss per share:
Basic and diluted (in dollars per share)	$ (0.002)	$ (0.013)	$ (0.006)	$ (0.022)
Weighted average shares outstanding, basic and diluted (in shares)	203,710,642	70,103,698	200,016,816	69,358,355

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	345,000	68,474,520
Balance at Dec. 31, 2018	$ 69	$ 13,695	$ 2,166,745	$ (3,639,808)	$ (1,459,299)
Net loss for the period				(298,323)	(298,323)
Common stock issued for liabilities (in shares)		199,017
Common stock issued for liabilities		$ 40	7,822		7,862
Balance (in shares) at Mar. 31, 2019	345,000	68,673,537
Balance at Mar. 31, 2019	$ 69	$ 13,735	2,174,567	(3,938,131)	(1,749,760)
Balance (in shares) at Dec. 31, 2018	345,000	68,474,520
Balance at Dec. 31, 2018	$ 69	$ 13,695	2,166,745	(3,639,808)	(1,459,299)
Notes payable converted to common stock
Net loss for the period					(1,519,561)
Stock options exchanged for common stock
Balance (in shares) at Sep. 30, 2019	345,000	70,190,699
Balance at Sep. 30, 2019	$ 69	$ 14,038	3,065,763	(5,159,369)	(2,079,499)
Balance (in shares) at Mar. 31, 2019	345,000	68,673,537
Balance at Mar. 31, 2019	$ 69	$ 13,735	2,174,567	(3,938,131)	(1,749,760)
Net loss for the period				(285,850)	(285,850)
Common stock issued for liabilities (in shares)		273,469
Common stock issued for liabilities		$ 54	11,138		11,192
Common stock issued for services (in shares)		972,668
Common stock issued for services		$ 195	29,496		29,691
Balance (in shares) at Jun. 30, 2019	345,000	69,919,674
Balance at Jun. 30, 2019	$ 69	$ 13,984	2,215,201	(4,223,981)	(1,994,727)
Net loss for the period				(935,388)	(935,388)
Options issued for compensation and services			840,500		840,500
Common stock issued for services (in shares)		271,025
Common stock issued for services		$ 54	10,062		10,116
Balance (in shares) at Sep. 30, 2019	345,000	70,190,699
Balance at Sep. 30, 2019	$ 69	$ 14,038	3,065,763	(5,159,369)	(2,079,499)
Balance (in shares) at Dec. 31, 2019	345,000	193,521,506
Balance at Dec. 31, 2019	$ 69	$ 38,704	6,135,885	(5,494,193)	680,465
Warrants issued			53,447		53,447
Notes payable converted to common stock (in shares)		9,129,136
Notes payable converted to common stock		$ 1,826	298,174		300,000
Beneficial converson feature of note payable			310,303		310,303
Net loss for the period				(530,307)	(530,307)
Balance (in shares) at Mar. 31, 2020	345,000	202,650,642
Balance at Mar. 31, 2020	$ 69	$ 40,530	6,797,809	(6,024,500)	813,908
Balance (in shares) at Dec. 31, 2019	345,000	193,521,506
Balance at Dec. 31, 2019	$ 69	$ 38,704	6,135,885	(5,494,193)	680,465
Notes payable converted to common stock					300,000
Net loss for the period					$ (1,254,043)
Exchange of stock options for common shares (in shares)					1,800,000
Stock options exchanged for common stock					$ 360
Balance (in shares) at Sep. 30, 2020	345,000	204,450,642
Balance at Sep. 30, 2020	$ 69	$ 40,890	7,353,503	(6,748,236)	646,226
Balance (in shares) at Mar. 31, 2020	345,000	202,650,642
Balance at Mar. 31, 2020	$ 69	$ 40,530	6,797,809	(6,024,500)	813,908
Warrants issued			23,692		23,692
Beneficial converson feature of note payable			191,839		191,839
Net loss for the period				(289,632)	(289,632)
Exchange of stock options for common shares (in shares)		900,000
Stock options exchanged for common stock		$ 180	(180)
Balance (in shares) at Jun. 30, 2020	345,000	203,550,642
Balance at Jun. 30, 2020	$ 69	$ 40,710	7,013,160	(6,314,132)	739,807
Warrants issued			31,454		31,454
Beneficial converson feature of note payable			235,296		235,296
Net loss for the period				(434,104)	(434,104)
Exchange of stock options for common shares (in shares)		900,000
Stock options exchanged for common stock		$ 180	(180)
Options issued for compensation and services			73,773		73,773
Balance (in shares) at Sep. 30, 2020	345,000	204,450,642
Balance at Sep. 30, 2020	$ 69	$ 40,890	$ 7,353,503	$ (6,748,236)	$ 646,226

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		64 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Cash Flows from Operating Activities
Net loss	$ (434,104)	$ (530,307)	$ (935,388)	$ (298,323)	$ (1,254,043)	$ (1,519,561)	$ 6,748,236
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation					126	567
Amortization - patents					60,172	60,172
Amortization - debt discount					296,738	45,134
Options issued for services					73,773	724,631
Common stock issued for services						39,807
Change in:
Prepaid expenses					(89,579)	11,229
Deposits					2,315
Accounts payable and accrued liabilities					(124,160)	409,381
Net cash used in operating activities					(1,034,659)	(228,640)
Cash Flows from Financing Activities
Payments on insurance premium financing					(46,986)	(36,680)
Proceeds from debt and warrants issued					1,047,151	270,000
Net cash provided by financing activities					1,000,165	233,320
Net change in cash					(34,494)	4,680
Cash, beginning of period		58,149		$ 4,001	58,149	4,001
Cash, end of period	23,655		$ 8,681		23,655	8,681	$ 23,655
Supplemental Disclosure of Cash flow Information
Cash paid during the period for interest					50,271	2,921
Non-Cash Financing Activities
Notes payable converted to common stock		$ 300,000			300,000
Stock options exchanged for common stock					360
Options issued for accounts payable						115,869
Common stock issued to satisfy liabilities						19,054
Recognition of beneficial conversion feature					$ 737,437

Note 1 - Business Organization,

Note 1 - Business Organization, Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 Nature of Business The Coretec Group Inc. (the “Group”) (formerly 3DIcon “3DIcon” August 11, 1995, August 1, 2003 3DIcon 2001, 360 January 1, 2001, 3DIcon's 3D Coretec Industries, LLC (“Coretec”), a wholly owned subsidiary of the Group (collectively the “Company”), was organized on June 2, 2015 not Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures made are adequate to make the information presented not 10 may not may

Note 2 - Going Concern and Mana

Note 2 - Going Concern and Management's Plans	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company has realized a cumulative net loss of $6,748,236 June 2, 2015) September 30, 2020, $359,144 no The ability of the Company to continue as a going concern depends on the successful completion of the Company's capital raising efforts to fund the development of its planned products. The Company intends to continue to raise additional capital through debt and equity financings. There is no may not may The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates the continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the condensed consolidated financial statements do not not

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Principles of Consolidation The condensed consolidated financial statements include the accounts of the Group and its wholly owned subsidiary, Coretec. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used. Long-Lived Assets Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not first not third Reclassification Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications apply only to the Statement of Operations and have no Fair Value of Financial Instruments The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company: Current assets and current liabilities Notes payable - Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, The beneficial conversion feature of a convertible note is credited to additional paid-in-capital. The intrinsic value is recorded in the condensed consolidated financial statements as a debt discount and such discount is amortized over the expected term of the convertible note and is charged to interest expense. Earnings(Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing net income or loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Diluted loss per common share is calculated the same as basic loss per common share for all periods presented because the exercise or conversion of the securities and other instruments would be anti-dilutive due to the net loss. The following securities and other instruments to issue common stock are excluded from the calculation of weighted average dilutive common shares: September 30 , 2020 2019 Options 20,212,174 20,716,557 Warrants 1,770,000 61 Series A convertible preferred stock 115,000 115,000 Convertible debt 35,755,783 253,106,815 Total potentially dilutive shares 57,852,957 273,938,433 Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not 6. Recent Accounting Pronouncements The following is a summary of recent accounting pronouncements that are relevant to the Company: In January 2017, 2017 04, Intangibles – Goodwill and Other (Topic 350 ): Simplifying the Test for Goodwill Impairment 2 2, January 1, 2020 not In August 2020, 2020 06, Debt with Conversion and Other Options (Subtopic 470 20 815 40 No. 2020 06, no No. 2020 06 first 2024, first 2021, may No. 2020 06,

Note 4 - Notes Payable

Note 4 - Notes Payable	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 September 30, December 31, 2020 2019 Notes payable: 6.3% Insurance premium finance agreement due July 2020 $ - $ 39,138 3.8% Insurance premium finance agreement due June 2021 69,545 - Notes payable - related party: 10% Promissory note due January 2024 1,175,000 475,000 Less: Beneficial conversion feature (773,317 ) (273,422 ) Warrants issued (123,001 ) (59,108 ) Debt issue costs (37,709 ) (21,962 ) Total notes payable - related party $ 240,973 $ 120,508 6.3% July 2020 The Company entered into an insurance financing agreement in September 2019 $61,503. eleven $5,591. July 2020. 3. 8 % Insurance premium finance agreement, due June 2021 The Company entered into an insurance financing agreement in August 2020 $77,151. ten $7,849. first September 2020. 10% January 2024, On October 4, 2019, 10% $2,500,000, January 15, 2024 3,000,000 $0.052 sixteen 16 $125,000 $175,000 October 2019. first 12 36 Under the terms of the Promissory Note, DAF has the right to elect to convert all or part of the Promissory Note at a price equal to seventy 70% fifteen 15 October 4, 2019, $0.0329 The embedded conversion option was deemed to be a beneficial conversion feature because the active conversion price was less than the commitment date market price of the common stock. Given the terms and related-party nature of the agreement, the commitment date was determined to be the date the funds are advanced to the Company and is limited to the funding value less other debt discounts (see below). A debt discount of $737,437 $281,837 nine September 30, 2020 December 31, 2019, $107,552 nine September 30, 2020. Under the terms of the DAF Credit Agreement, warrants to subscribe for and purchase 3,000,000 $0.052 150,000 210,000 1.2 $1 September 30, 2020, 1,770,000 $108,594 $60,593 nine September 30, 2020 December 31, 2019, $19,398 nine September 30, 2020. Additionally, under the terms of the Credit Agreement, the Company agreed to pay a commitment fee of 3% $30,000 $22,767 nine September 30, 2020 December 31, 2019 $6,080 nine September 30, 2020. On March 31, 2020, $300,000 9,129,136 $0.0329 $130,370 $25,523 $8,123

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 5 Warrants Under the terms of the DAF Credit Agreement, warrants to subscribe for and purchase 3,000,000 $0.052 150,000 210,000 1.2 $1 September 30, 2020, 1,770,000 Warrants Summary The following table summarizes the Company's warrant activity during the nine September 30, 2020: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2019 570,000 $ 0.052 Granted 1,200,000 0.052 Outstanding, September 30, 2020 1,770,000 $ 0.052 4.44 $ - Options Stock options for employees, directors or consultants that vest immediately, are valued at the date of award, which does not The estimated fair value of options for common stock granted is determined using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the option is based on historical exercise behavior and expected future experience. The following table summarizes the Company's option activity during the nine September 30, 2020: Weighted Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2019 21,716,557 $ 0.076 Expired (4,383 ) 52.50 Exchanged for common stock (3,000,000 ) 0.041 Granted 1,500,000 0.057 Outstanding, September 30, 2020 20,212,174 $ 0.068 3.95 $ - Exercisable, September 30, 2020 19,212,174 $ 0.068 3.90 $ - On June 8, 2020, 21,500,000 August 7, 2019. 144 0.6 1 not no September 30, 2020, 3,000,000 1,800,000 The following table summarizes the Company's options as of September 30, 2020: Weighted Average Outstanding Remaining Exercisable Exercise Number of Life Number of Price Options In Years Options $ 0.041 19,000,000 3.88 19,000,000 $ 0.065 1,000,000 4.75 - $ 0.240 208,160 6.47 208,160 $ 70.260 3,449 1.75 3,449 $ 420.000 565 0.62 565 Total 20,212,174 3.95 19,212,174 Litigation, Claims, and Assessments The Company may not Office Leases and rent expenses The Company had an amended office lease in Tulsa, Oklahoma that expired on July 31, 2018. $1,980 June 23, 2020 Additionally, on December 3, 2019, one January 1, 2020. $7,560 $1,260 September 30, 2020. Rent expense for the operating leases was $22,134 $17,820 nine September 30, 2020 2019, Supply Agreement During June 2020, Si6H12 $185,000 500 March 31, 2021. $92,500 July 20, 2020,

Note 6 - Subsequent Events

Note 6 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 6 Common stock issuance Subsequent to September 30, 2020, 500,000 Securities Market On October 29, 2020, $12,000 one $2,500. Conversion of convertible debt On October 30, 2020, $250,000 $0.0329 7,598,784

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Group and its wholly owned subsidiary, Coretec. Intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.
Property, Plant and Equipment, Policy [Policy Text Block]	Long-Lived Assets Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not first not third
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications apply only to the Statement of Operations and have no
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company: Current assets and current liabilities Notes payable -
Debt Instrument, Convertible, Beneficial Conversion Feature [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, The beneficial conversion feature of a convertible note is credited to additional paid-in-capital. The intrinsic value is recorded in the condensed consolidated financial statements as a debt discount and such discount is amortized over the expected term of the convertible note and is charged to interest expense.
Earnings Per Share, Policy [Policy Text Block]	Earnings(Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing net income or loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Diluted loss per common share is calculated the same as basic loss per common share for all periods presented because the exercise or conversion of the securities and other instruments would be anti-dilutive due to the net loss. The following securities and other instruments to issue common stock are excluded from the calculation of weighted average dilutive common shares: September 30 , 2020 2019 Options 20,212,174 20,716,557 Warrants 1,770,000 61 Series A convertible preferred stock 115,000 115,000 Convertible debt 35,755,783 253,106,815 Total potentially dilutive shares 57,852,957 273,938,433
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not 6.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The following is a summary of recent accounting pronouncements that are relevant to the Company: In January 2017, 2017 04, Intangibles – Goodwill and Other (Topic 350 ): Simplifying the Test for Goodwill Impairment 2 2, January 1, 2020 not In August 2020, 2020 06, Debt with Conversion and Other Options (Subtopic 470 20 815 40 No. 2020 06, no No. 2020 06 first 2024, first 2021, may No. 2020 06,

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30 , 2020 2019 Options 20,212,174 20,716,557 Warrants 1,770,000 61 Series A convertible preferred stock 115,000 115,000 Convertible debt 35,755,783 253,106,815 Total potentially dilutive shares 57,852,957 273,938,433

Note 4 - Notes Payable (Tables)

Note 4 - Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	September 30, December 31, 2020 2019 Notes payable: 6.3% Insurance premium finance agreement due July 2020 $ - $ 39,138 3.8% Insurance premium finance agreement due June 2021 69,545 - Notes payable - related party: 10% Promissory note due January 2024 1,175,000 475,000 Less: Beneficial conversion feature (773,317 ) (273,422 ) Warrants issued (123,001 ) (59,108 ) Debt issue costs (37,709 ) (21,962 ) Total notes payable - related party $ 240,973 $ 120,508

Note 5 - Commitments and Cont_2

Note 5 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Warrant Activity [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2019 570,000 $ 0.052 Granted 1,200,000 0.052 Outstanding, September 30, 2020 1,770,000 $ 0.052 4.44 $ -
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Weighted Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2019 21,716,557 $ 0.076 Expired (4,383 ) 52.50 Exchanged for common stock (3,000,000 ) 0.041 Granted 1,500,000 0.057 Outstanding, September 30, 2020 20,212,174 $ 0.068 3.95 $ - Exercisable, September 30, 2020 19,212,174 $ 0.068 3.90 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Average Outstanding Remaining Exercisable Exercise Number of Life Number of Price Options In Years Options $ 0.041 19,000,000 3.88 19,000,000 $ 0.065 1,000,000 4.75 - $ 0.240 208,160 6.47 208,160 $ 70.260 3,449 1.75 3,449 $ 420.000 565 0.62 565 Total 20,212,174 3.95 19,212,174

Note 2 - Going Concern and Ma_2

Note 2 - Going Concern and Management's Plans (Details Textual) - USD ($)	3 Months Ended						9 Months Ended		64 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Net Income (Loss) Attributable to Parent, Total	$ (434,104)	$ (289,632)	$ (530,307)	$ (935,388)	$ (285,850)	$ (298,323)	$ (1,254,043)	$ (1,519,561)	$ 6,748,236
Working Capital Deficit	359,144						359,144		359,144
Revenue from Contract with Customer, Including Assessed Tax									$ 0

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Total potentially dilutive shares (in shares)	57,852,957	273,938,433
Options [Member]
Total potentially dilutive shares (in shares)	20,212,174	20,716,557
Warrant [Member]
Total potentially dilutive shares (in shares)	1,770,000	61
Series A Convertible Preferred Stock [Member]
Total potentially dilutive shares (in shares)	115,000	115,000
Convertible Debt Securities [Member]
Total potentially dilutive shares (in shares)	35,755,783	253,106,815

Note 4 - Notes Payable (Details

Note 4 - Notes Payable (Details Textual)	Mar. 31, 2020USD ($)$ / sharesshares	Oct. 04, 2019USD ($)$ / sharesshares	Aug. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)$ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 0.052		$ 0.052
Amortization of Debt Discount (Premium)					$ 296,738	$ 45,134
Class of Warrant or Right, Issued Monthly (in shares) | shares					1,200,000
Conversion of DAF Promissory Note into Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.0329
Amortization of Debt Discount (Premium)	$ 130,370
Allocated Cost of Warrants	25,523
Debt Agreement, Maximum Borrowing Capacity	$ 300,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	9,129,136
Deferred Costs, Total	$ 8,123
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares		3,000,000			3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.052			$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation (in shares) | shares		1.2			1.2
Class of Warrant or Right, Issued During Period (in shares) | shares					1,770,000
Allocated Cost of Warrants					$ 108,594		$ 60,593
Amortization Expense Associated With Warrants					$ 19,398
Warrant Issued in Connection With Credit Agreement [Member] | Minimum [Member]
Class of Warrant or Right, Issued Monthly (in shares) | shares		150,000			150,000
Warrant Issued in Connection With Credit Agreement [Member] | Maximum [Member]
Class of Warrant or Right, Issued Monthly (in shares) | shares		210,000			210,000
Six Point Three Percent Insurance Premium Finance Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage				6.30%		6.30%
Debt Instrument, Face Amount				$ 61,503		$ 61,503
Debt Instrument, Term (Month)				330 days
Debt Instrument, Periodic Payment, Total				$ 5,591
3.8% Insurance Premium Finance Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage			3.80%		3.80%
Debt Instrument, Face Amount			$ 77,151
Debt Instrument, Term (Month)			300 days
Debt Instrument, Periodic Payment, Total			$ 7,849
Credit Agreement And Note [Member]
Debt Instrument, Interest Rate, Stated Percentage		10.00%			10.00%		10.00%
Debt Agreement, Maximum Borrowing Capacity		$ 2,500,000
Debt Instrument, Number of Tranches		16
Debt Instrument, Period of Monthly Advance Interest Payments (Month)		1 year
Debt Instrument, Period Following Advance Interest Payments (Month)		3 years
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		70.00%
Debt Instrument, Convertible, Threshold Trading Days		15
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 0.0329
Debt Instrument, Unamortized Discount, Total					$ 737,437		$ 281,837
Amortization of Debt Discount (Premium)					107,552
Line of Credit Facility, Commitment Fee Percentage		3.00%
Line of Credit Facility, Commitment Fee and Debt-related Expenses to Be Amortized					30,000		$ 22,767
Amortization Associated With Commitment Fee					$ 6,080
Credit Agreement And Note [Member] | Minimum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche		$ 125,000
Credit Agreement And Note [Member] | Maximum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche		$ 175,000

Note 4 - Notes Payable - Schedu

Note 4 - Notes Payable - Schedule of Debt (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Notes payable	$ 69,545	$ 39,138
Notes Payable, Related Parties	240,973	120,508
Six Point Zero Five Percent Insurance Premium Finance Agreement, Due July 2019 [Member]
Notes payable		39,138
3.8% Insurance Premium Finance Agreement [Member]
Notes payable	69,545
Credit Agreement And Note [Member]
10% Promissory note due January 2024	1,175,000	475,000
Beneficial conversion feature	(773,317)	(273,422)
Warrants issued	(123,001)	(59,108)
Debt issue costs	$ (37,709)	$ (21,962)

Note 4 - Notes Payable - Sche_2

Note 4 - Notes Payable - Schedule of Debt (Details) (Parentheticals)	Sep. 30, 2020	Aug. 31, 2020	Dec. 31, 2019	Oct. 04, 2019
Six Point Zero Five Percent Insurance Premium Finance Agreement, Due July 2019 [Member]
Interest rate	6.30%		6.30%
3.8% Insurance Premium Finance Agreement [Member]
Interest rate	3.80%	3.80%
Credit Agreement And Note [Member]
Interest rate	10.00%		10.00%	10.00%

Note 5 - Commitments and Cont_3

Note 5 - Commitments and Contingencies (Details Textual)	Jul. 20, 2020USD ($)	Jun. 08, 2020shares	Oct. 04, 2019$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2019$ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.052		$ 0.052
Class of Warrant or Right, Issued Monthly (in shares)				1,200,000
Share Exchange Agreement, Number of Options Authorized (in shares)		21,500,000
Share Exchange Agreement, Exchange Ratio		0.6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exchanged (in shares)				3,000,000
Stock Issued During Period, Shares, Stock Options Exchanged for Common Shares (in shares)				1,800,000
Lessee, Operating Lease, Liability, to be Paid, Total | $				$ 7,560
Operating Lease, Expense | $				22,134	$ 17,820
Evonik Operations GmbH [Member]
Purchase Obligation, Total | $				185,000
Payments for Research and Development, Supply Agreement | $	$ 92,500
Tulsa, Oklahoma [Member]
Operating Leases, Rent Expense, Monthly | $				1,980
Ann Arbor, Michigan [Member]
Operating Leases, Rent Expense, Monthly | $				$ 1,260
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,000,000	3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.052	$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation (in shares)			1.2	1.2
Class of Warrant or Right, Issued During Period (in shares)				1,770,000
Warrant Issued in Connection With Credit Agreement [Member] | Minimum [Member]
Class of Warrant or Right, Issued Monthly (in shares)			150,000	150,000
Warrant Issued in Connection With Credit Agreement [Member] | Maximum [Member]
Class of Warrant or Right, Issued Monthly (in shares)			210,000	210,000

Note 5 - Commitments and Cont_4

Note 5 - Commitments and Contingencies - Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Outstanding, number of warrants (in shares) | shares	570,000
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.052
Granted, number of warrants (in shares) | shares	1,200,000
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.052
Outstanding, number of warrants (in shares) | shares	1,770,000
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.052
Outstanding, weighted-average remaining life (Year)	4 years 160 days
Outstanding, aggregate intrinsic value | $

Note 5 - Commitments and Cont_5

Note 5 - Commitments and Contingencies - Option Activity (Details)	9 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Exchanged for common stock (in shares)	(3,000,000)
Granted, Shares (in shares)	1,500,000
Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.057
Share-based Payment Arrangement, Option [Member]
Outstanding, Shares (in shares)	21,716,557
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.076
Outstanding, Weighted Average Remaining Life (Year)
Expired, Shares (in shares)	(4,383)
Expired, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 52.50
Exchanged for common stock (in shares)	(3,000,000)
Exchanged for common stock, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.041
Outstanding, Shares (in shares)	20,212,174
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.068
Outstanding, Weighted Average Remaining Life in Years (Year)	3 years 346 days
Outstanding, Aggregate intrinsic value | $
Exercisable, Shares (in shares)	19,212,174
Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.068
Exercisable, Weighted Average Remaining Life (Year)	3 years 328 days
Exercisable, Aggregate intrinsic value | $

Note 5 - Commitments and Cont_6

Note 5 - Commitments and Contingencies - Shares Authorized Under Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Option Outstanding, Number Of Options (in shares)	20,212,174
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 346 days
Option Exercisable, Number Of Options (in shares)	19,212,174
Option Exercisable, Number Of Options (in shares)	19,212,174
Exercise Price Range One [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.041
Option Outstanding, Number Of Options (in shares)	19,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 321 days
Option Exercisable, Number Of Options (in shares)	19,000,000
Option Exercisable, Number Of Options (in shares)	19,000,000
Exercise Price Range Two [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.065
Option Outstanding, Number Of Options (in shares)	1,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years 273 days
Option Exercisable, Number Of Options (in shares)
Option Exercisable, Number Of Options (in shares)
Exercise Price Range Three [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.24
Option Outstanding, Number Of Options (in shares)	208,160
Option Exercisable, Weighted Average Remaining Life In Years (Year)	6 years 171 days
Option Exercisable, Number Of Options (in shares)	208,160
Option Exercisable, Number Of Options (in shares)	208,160
Exercise Price Range Four [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 70.26
Option Outstanding, Number Of Options (in shares)	3,449
Option Exercisable, Weighted Average Remaining Life In Years (Year)	1 year 273 days
Option Exercisable, Number Of Options (in shares)	3,449
Option Exercisable, Number Of Options (in shares)	3,449
Exercise Price Range Five [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 420
Option Outstanding, Number Of Options (in shares)	565
Option Exercisable, Weighted Average Remaining Life In Years (Year)	226 days
Option Exercisable, Number Of Options (in shares)	565
Option Exercisable, Number Of Options (in shares)	565

Note 6 - Subsequent Events (Det

Note 6 - Subsequent Events (Details Textual) - USD ($)	Oct. 30, 2020	Oct. 29, 2020	Mar. 31, 2020	Nov. 12, 2020
Conversion of DAF Promissory Note into Common Stock [Member]
Debt Agreement, Maximum Borrowing Capacity			$ 300,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 0.0329
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			9,129,136
Subsequent Event [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)				500,000
Annual Fees for Listing on Market		$ 12,000
Application Fee for Listing on Market		$ 2,500
Subsequent Event [Member] | Conversion of DAF Promissory Note into Common Stock [Member]
Debt Agreement, Maximum Borrowing Capacity	$ 250,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.0329
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	7,598,784